|
Age, median (range), years
|
50.0 (21–71)
|
|
< 65 years, n (%)
|
46 (92.0)
|
|
≥ 65 years, n (%)
|
4 (8.0)
|
|
Sex, n (%)
|
|
Male
|
24 (48.0)
|
|
Female
|
26 (52.0)
|
|
Geographic region, n (%)
|
|
USA
|
27 (54.0)
|
|
Europe
|
22 (44.0)
|
|
Asia
|
1 (2.0)
|
|
ECOG PS, n (%)
|
|
0
|
19 (38.0)
|
|
1
|
31 (62.0)
|
|
Median time since first diagnosis (range), years
|
1.6 (0.2–15.1)
|
|
Median time since last disease progression (range), months
|
0.92 (0.33–8.61)
|
|
Number of prior lines of systemic anticancer therapy, n (%)
|
|
1
|
13 (26.0)
|
|
2
|
18 (36.0)
|
|
3
|
10 (20.0)
|
|
≥ 4
|
9 (18.0)
|
|
Receiving concomitant mitotane, n (%)
|
25 (50.0)
|
|
PD-L1 expression on tumor cells (≥1% cutoff), n (%)
|
|
Negative
|
27 (54.0)
|
|
Positive
|
15 (30.0)
|
|
Not evaluable
|
8 (16.0)
|
|
PD-L1 expression on tumor cells (≥5% cutoff), n (%)
|
|
Negative
|
30 (60.0)
|
|
Positive
|
12 (24.0)
|
|
Not evaluable
|
8 (16.0)
|
